{
 "cells": [
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# First implementation of a GNN (GCN)\n",
    "In this notebook, we build the graph from an initial dataframe, and we execute the first implementation of our GNN, which contains 1 convolutive layer and 1 fully-connected layer.\n",
    "\n",
    "## Notebook plan : \n",
    "1. Building the graph\n",
    "2. Building the GCN"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from models.BuildGraph import BuildGraph"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Building the graph\n",
    "Here, we split the patients by tumour type. We merge tumour types if they contain only 1 patient."
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Reading the dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Anonymous ID</th>\n",
       "      <th>EGA ID</th>\n",
       "      <th>Tumour type</th>\n",
       "      <th>Sex</th>\n",
       "      <th>Line of therapy</th>\n",
       "      <th>Immunotherapy regimen</th>\n",
       "      <th>Cohort</th>\n",
       "      <th>Reason for discontinuation</th>\n",
       "      <th>Best response</th>\n",
       "      <th>Age at advanced disease diagnosis</th>\n",
       "      <th>...</th>\n",
       "      <th>Alive_0</th>\n",
       "      <th>Time to progression (days)</th>\n",
       "      <th>Progression_1</th>\n",
       "      <th>Clinical benefit</th>\n",
       "      <th>CD8+ T cell score</th>\n",
       "      <th>Exome mut per mb</th>\n",
       "      <th>Genome mut per mb</th>\n",
       "      <th>CD274 expression</th>\n",
       "      <th>M1M2 expression</th>\n",
       "      <th>Lymph related</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>14891</td>\n",
       "      <td>EGAD00001001961</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>F</td>\n",
       "      <td>8</td>\n",
       "      <td>Nivolumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Mixed</td>\n",
       "      <td>45</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>179</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.351869</td>\n",
       "      <td>11.095310</td>\n",
       "      <td>23.0729</td>\n",
       "      <td>4.1689</td>\n",
       "      <td>55.51575</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>18624</td>\n",
       "      <td>EGAD00001002047</td>\n",
       "      <td>AECA</td>\n",
       "      <td>F</td>\n",
       "      <td>10</td>\n",
       "      <td>Nivolumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Stable disease</td>\n",
       "      <td>47</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>148</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.071464</td>\n",
       "      <td>3.876336</td>\n",
       "      <td>5.4552</td>\n",
       "      <td>0.7910</td>\n",
       "      <td>9.32352</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>21392</td>\n",
       "      <td>EGAD00001002544</td>\n",
       "      <td>OV</td>\n",
       "      <td>F</td>\n",
       "      <td>6</td>\n",
       "      <td>Monalizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Physician assessed SD</td>\n",
       "      <td>57</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>79</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.040394</td>\n",
       "      <td>2.415688</td>\n",
       "      <td>4.1274</td>\n",
       "      <td>4.0377</td>\n",
       "      <td>50.12008</td>\n",
       "      <td>Lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21516</td>\n",
       "      <td>EGAD00001002546</td>\n",
       "      <td>SKCM</td>\n",
       "      <td>F</td>\n",
       "      <td>3</td>\n",
       "      <td>Ipilimumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Death</td>\n",
       "      <td>Not evaluable</td>\n",
       "      <td>29</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>11</td>\n",
       "      <td>0</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.052774</td>\n",
       "      <td>6.235845</td>\n",
       "      <td>11.4871</td>\n",
       "      <td>0.6006</td>\n",
       "      <td>1.58550</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>22186</td>\n",
       "      <td>EGAD00001001966</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>F</td>\n",
       "      <td>4</td>\n",
       "      <td>Atezolizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Stable disease</td>\n",
       "      <td>52</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>80</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.009323</td>\n",
       "      <td>4.606660</td>\n",
       "      <td>7.1503</td>\n",
       "      <td>1.8234</td>\n",
       "      <td>38.42695</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>39280</td>\n",
       "      <td>EGAD00001004933</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>M</td>\n",
       "      <td>2</td>\n",
       "      <td>Pembrolizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>Physician Assessed SD</td>\n",
       "      <td>60</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>401</td>\n",
       "      <td>0</td>\n",
       "      <td>DCB</td>\n",
       "      <td>0.695396</td>\n",
       "      <td>84.998501</td>\n",
       "      <td>96.4079</td>\n",
       "      <td>8.4768</td>\n",
       "      <td>86.62561</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>37899</td>\n",
       "      <td>EGAD00001005838</td>\n",
       "      <td>CHOL</td>\n",
       "      <td>F</td>\n",
       "      <td>2</td>\n",
       "      <td>Nivolumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Death</td>\n",
       "      <td>Physician assessed PR</td>\n",
       "      <td>38</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>96</td>\n",
       "      <td>0</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.818233</td>\n",
       "      <td>2.247151</td>\n",
       "      <td>2.7416</td>\n",
       "      <td>11.2704</td>\n",
       "      <td>47.97376</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>37775</td>\n",
       "      <td>EGAD00001004934</td>\n",
       "      <td>HNSC</td>\n",
       "      <td>M</td>\n",
       "      <td>1</td>\n",
       "      <td>Avelumab/OX40 agonist PF-04518600</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Stable disease</td>\n",
       "      <td>69</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>69</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.018982</td>\n",
       "      <td>3.848247</td>\n",
       "      <td>5.8036</td>\n",
       "      <td>8.7136</td>\n",
       "      <td>5.13403</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>38313</td>\n",
       "      <td>EGAD00001005844</td>\n",
       "      <td>ACC</td>\n",
       "      <td>F</td>\n",
       "      <td>3</td>\n",
       "      <td>Avelumab/Debio1143 (SMAC mimetic)</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>Partial response</td>\n",
       "      <td>34</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>51</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>5.617878</td>\n",
       "      <td>7.7940</td>\n",
       "      <td>0.0688</td>\n",
       "      <td>0.51364</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>38207</td>\n",
       "      <td>EGAD00001005850</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>F</td>\n",
       "      <td>1</td>\n",
       "      <td>Pembrolizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Physician assessed SD</td>\n",
       "      <td>50</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>104</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.110416</td>\n",
       "      <td>33.763449</td>\n",
       "      <td>53.2769</td>\n",
       "      <td>23.8818</td>\n",
       "      <td>11.22022</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>82 rows Ã— 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       "0          14891  EGAD00001001961        LUNG   F               8  \\\n",
       "1          18624  EGAD00001002047        AECA   F              10   \n",
       "2          21392  EGAD00001002544          OV   F               6   \n",
       "3          21516  EGAD00001002546        SKCM   F               3   \n",
       "4          22186  EGAD00001001966        LUNG   F               4   \n",
       "..           ...              ...         ...  ..             ...   \n",
       "92         39280  EGAD00001004933        LUNG   M               2   \n",
       "94         37899  EGAD00001005838        CHOL   F               2   \n",
       "95         37775  EGAD00001004934        HNSC   M               1   \n",
       "96         38313  EGAD00001005844         ACC   F               3   \n",
       "97         38207  EGAD00001005850        LUNG   F               1   \n",
       "\n",
       "                Immunotherapy regimen Cohort Reason for discontinuation   \n",
       "0                           Nivolumab  Naive                Progression  \\\n",
       "1                           Nivolumab  Naive                Progression   \n",
       "2                         Monalizumab  Naive                Progression   \n",
       "3                          Ipilimumab  Naive                      Death   \n",
       "4                        Atezolizumab  Naive                Progression   \n",
       "..                                ...    ...                        ...   \n",
       "92                      Pembrolizumab  Naive                   Toxicity   \n",
       "94                          Nivolumab  Naive                      Death   \n",
       "95  Avelumab/OX40 agonist PF-04518600  Naive                Progression   \n",
       "96  Avelumab/Debio1143 (SMAC mimetic)  Naive                   Toxicity   \n",
       "97                      Pembrolizumab  Naive                Progression   \n",
       "\n",
       "            Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       "0                   Mixed                                 45  ...        1  \\\n",
       "1          Stable disease                                 47  ...        1   \n",
       "2   Physician assessed SD                                 57  ...        1   \n",
       "3           Not evaluable                                 29  ...        1   \n",
       "4          Stable disease                                 52  ...        1   \n",
       "..                    ...                                ...  ...      ...   \n",
       "92  Physician Assessed SD                                 60  ...        1   \n",
       "94  Physician assessed PR                                 38  ...        1   \n",
       "95         Stable disease                                 69  ...        1   \n",
       "96       Partial response                                 34  ...        1   \n",
       "97  Physician assessed SD                                 50  ...        0   \n",
       "\n",
       "    Time to progression (days)  Progression_1  Clinical benefit   \n",
       "0                          179              1               NCB  \\\n",
       "1                          148              1               NCB   \n",
       "2                           79              1               NCB   \n",
       "3                           11              0               NCB   \n",
       "4                           80              1               NCB   \n",
       "..                         ...            ...               ...   \n",
       "92                         401              0               DCB   \n",
       "94                          96              0               NCB   \n",
       "95                          69              1               NCB   \n",
       "96                          51              1               NCB   \n",
       "97                         104              1               NCB   \n",
       "\n",
       "   CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       "0           0.351869         11.095310            23.0729            4.1689  \\\n",
       "1           0.071464          3.876336             5.4552            0.7910   \n",
       "2           0.040394          2.415688             4.1274            4.0377   \n",
       "3           0.052774          6.235845            11.4871            0.6006   \n",
       "4           0.009323          4.606660             7.1503            1.8234   \n",
       "..               ...               ...                ...               ...   \n",
       "92          0.695396         84.998501            96.4079            8.4768   \n",
       "94          0.818233          2.247151             2.7416           11.2704   \n",
       "95          0.018982          3.848247             5.8036            8.7136   \n",
       "96          0.000000          5.617878             7.7940            0.0688   \n",
       "97          0.110416         33.763449            53.2769           23.8818   \n",
       "\n",
       "    M1M2 expression      Lymph related  \n",
       "0          55.51575  Non-lymph related  \n",
       "1           9.32352  Non-lymph related  \n",
       "2          50.12008      Lymph related  \n",
       "3           1.58550  Non-lymph related  \n",
       "4          38.42695  Non-lymph related  \n",
       "..              ...                ...  \n",
       "92         86.62561  Non-lymph related  \n",
       "94         47.97376  Non-lymph related  \n",
       "95          5.13403  Non-lymph related  \n",
       "96          0.51364  Non-lymph related  \n",
       "97         11.22022  Non-lymph related  \n",
       "\n",
       "[82 rows x 21 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_excel('data/Supplemental-table1.xlsx')\n",
    "df = df.loc[df[\"Cohort\"] == \"Naive\"]\n",
    "df"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Split the patients per tumour type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There will be 9 distinct complete subgraphs.\n"
     ]
    }
   ],
   "source": [
    "buildgraph = BuildGraph(df)\n",
    "\n",
    "dico_tumour_type = buildgraph.split_per_column(\"Tumour type\",3)\n",
    "print(f\"There will be {len(list(dico_tumour_type.keys()))} distinct complete subgraphs.\")"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Compute the adjacency matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[0., 1., 1., ..., 0., 0., 0.],\n",
       "       [1., 0., 1., ..., 0., 0., 0.],\n",
       "       [1., 1., 0., ..., 0., 0., 0.],\n",
       "       ...,\n",
       "       [0., 0., 0., ..., 0., 1., 1.],\n",
       "       [0., 0., 0., ..., 1., 0., 1.],\n",
       "       [0., 0., 0., ..., 1., 1., 0.]])"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "A_tumour_type = buildgraph.global_adjacency_matrix(dico_tumour_type)\n",
    "A_tumour_type"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Vizualize graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x700 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "buildgraph.show_graph(A_tumour_type, \"Vizualization of the graph splitted by tumour type\",\"tumour-type.png\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.6"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
